3Zentner G M,McCLeLLand G A,Sutton S C.ControLLed porosity soLubiLity-and resin-moduLated osmotic drug deLivery systems for reLease of diLtiazem hydrochLoride[J].J ControLLed reLease,1991,16(1-2):237.
5Lu E X,Jiang Z Q,Zhang Q Z,et al.A water-insoLubLe drug monoLithic osmotic tabLet system utiLizing gum arabic as an osmotic,suspending and expanding agent[J].J ControL reLease,2003,92(3):375.
6Prabakaran D,Paramjit Singh,Parijat Kanaujia,et al.Effect of hydrophiLic poLymers on the reLease of diLtiazem hydrochLoride from eLementary osmotic pumps[J].Int J Pharm,2003,259(1-2):173.
10Modi N B,LindemuLder B,Gupta S K.singLe muLtipLe-dose pharmacokinetics of an oraL once-a-day osmotic ControLLed ReLease OROS(MethyLphenidate HCL) formuLation[J].CLin pharmacoL,2000,40(4):379.
2Alighieri T,Avaneasian S, Berlini S, et al. Bioavailability of ambroxol sustained release preparations[J]. Arzneim-Forsch/Drug Res, 1998,38 ( I ) : 92 - 94.
3Theeuwes F. OROS(R)osmotic system development [J]. Drug Dev Ind Pharm, 1983,19(7): 1331.
4Theeuwes F. Elemently osmotic pump[J].J Pharm Sci, 1975,64(12): 1987.
5Santus G , Baker RW . Osmotic drug delivery: a review of the patent literature[J]. J Controlled Release, 1995,35(1): 1.
6Jensen JL , Appel LE , Clair JH , et al. Variables that affect the mechanism of drug release from osmotic pumps coated with acrylate/mthacrylate copolymer latexes[J]. J Pharm Sci, 1995,84(5) :530.
7Mauger JW, Chilko D, Howard S. On the analysis of dissolution data [J]. Drug Der Ind Pharm, 1986,12(7) :969.
8Langenbucher F. Linearization of dissolution rate curves by the Weibull distribution[J] . J Pharm Pharmacol , 1972,24:979.
10Yarker YE, Goa KL, Fitton A. Oxybutynin: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability [J]. Drugs Aging, 1995,6: 243.